Find information on thousands of medical conditions and prescription drugs.

Tolterodine

Tolterodine (ATC code: G04BD) is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade name Detrol. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective. Tolterodine, however, although it acts on two types of receptors, has less side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are less side effects eg. hyposalivation, constipation, decreased gastric motility.

Read more at Wikipedia.org


[List your site here Free!]


Tolterodine Safe, Effective When Taken Over a 2-Year Period
From OB/GYN News, 2/1/01

HILTON HEAD ISLAND, S.C. -- Tolterodine tartrate given at a dosage of 2 mg twice daily for the treatment of overactive bladder maintains its efficacy over a 2-year period and becomes more tolerable with time, according to the results of a study of more than 700 patients.

"The incidence of adverse effects actually decreased over 2 years, and only 1.1% of patients withdrew because of dry mouth," study investigator Dr. Harold Drutz said at the annual meeting of the American Urogynecologic Society.

Until now the long-term safety and efficacy of tolterodine (Detrol) has not been documented. The study showed that there was an average 22% drop in daily micturition episodes and an 81% drop in daily incontinence episodes after 1 year of treatment. Those improvements were maintained over the course of a second year of follow-up.

In addition, the incidence of side effects decreased from 79% in the first year to 71% in the second year, said Dr. Drutz, who is professor and head of the section of urogynecology at the University of Toronto. The most common side effect reported was dry mouth, occurring at a rate of 36% in the first year and 19% in the second year.

A total of 80% of the patients completed the second year of treatment, with 6.5% withdrawing because of side effects and 13.5% withdrawing due to other reasons such as insufficient drug efficacy protocol violation, and consent withdrawal. Among those who withdrew, eight (1.1%) said they quit because of dry mouth. Other side effects that led to study withdrawal were "scattered among the different body systems," Dr. Drutz said at the meeting, cosponsored by the American College of Obstetricians and Gynecologists.

The study was supported by a grant from the Pharmacia Corp., which markets the drug.

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Tolterodine
Home Contact Resources Exchange Links ebay